Grünenthal hires ex-AstraZeneca as CCO; debuts promissory note

German family-owned pharma company Grünenthal Group today announces that Mark Fladrich has taken office as new chief commercial officer (CCO).

Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mr Fladrich served as area vice President, Southern and Western Europe for Anglo-Swedish drug major AstraZeneca (LSE: AZN).

The 57-year-old Australian brings a broad variety of expertise to Grünenthal – from in-market knowledge to regional and global sales and marketing roles. Mr Fladrich has almost 30 years of experience in the pharmaceutical industry. This includes large country management roles with AstraZeneca in Germany and Australia/New Zealand with over $1 billion of sales revenue in each country under his responsibility. He was also globally responsible for all Phase III products and promoted brands and for providing commercial input into R&D for all stages of clinical development.